Double-Blind, Parallel-Group Comparison of 23 mg Donepezil SR to 10 mg Donepezil IR in Patients with Moderate to Severe Alzheimer's disease

Trial Profile

Double-Blind, Parallel-Group Comparison of 23 mg Donepezil SR to 10 mg Donepezil IR in Patients with Moderate to Severe Alzheimer's disease

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 01 Feb 2017 Results of a subgroup analysis assessing the safety and efficacy of donepezil 23 mg/day compared with donepezil 10 mg/day in Asian patients with moderate-to-severe Alzheimer's disease, published in the Acta Neurologica Scandinavica.
    • 04 Jul 2012 Planned number of patients changed from 1200 to 1600 as reported by European Clinical Trials Database. (Parent trial: EudraCT2006-004888-54)
    • 04 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database. (Parent trial: EudraCT2006-004888-54)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top